Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Katharina Brück; Richard P. Meijer; Joost L. Boormans; de CRAC-studiegroep en de BlaZIB-studiegroep; Lambertus A. Kiemeney; J. Alfred Witjes; Lisa M.C. van Hoogstraten; Michiel S. van der Heijden; A. Rogier Donders; Martine Franckena; Carin A. Uyl-de Groot; Annemarie M. Leliveld-Kors; Katja K.H. Aben; Maarten C.C.M. Hulshof

doi:10.1007/s13629-026-00494-8

Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Translated title of the contribution: Muscle-invasive bladder cancer in the Netherlands: oncological outcomes after radical cystectomy and bladder-sparing therapy

Katharina Brück^*
, Richard P. Meijer
, Joost L. Boormans
, de CRAC-studiegroep en de BlaZIB-studiegroep
, Lambertus A. Kiemeney
, J. Alfred Witjes
, Lisa M.C. van Hoogstraten
, Michiel S. van der Heijden
, A. Rogier Donders
, Martine Franckena
, Carin A. Uyl-de Groot
, Annemarie M. Leliveld-Kors
, Katja K.H. Aben
, Maarten C.C.M. Hulshof

^*Corresponding author for this work

Amsterdam UMC
Utrecht University
Radboud University Medical Center
Integraal Kankercentrum Nederland
Netherlands Cancer Institute
University Medical Centre Groningen

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Abstract

Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

Translated title of the contribution	Muscle-invasive bladder cancer in the Netherlands: oncological outcomes after radical cystectomy and bladder-sparing therapy
Original language	Dutch
Pages (from-to)	59–67
Number of pages	9
Journal	Tijdschrift voor Urologie
Volume	16
Issue number	2-3
DOIs	https://doi.org/10.1007/s13629-026-00494-8
Publication status	Published - 2 Mar 2026

Bibliographical note

Publisher Copyright: © The Author(s) 2026.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s13629-026-00494-8Licence: CC BY

s13629-026-00494-8Final published version, 793 KBLicence: CC BY

Cite this

Brück, K., Meijer, R. P., Boormans, J. L., de CRAC-studiegroep en de BlaZIB-studiegroep, Kiemeney, L. A., Witjes, J. A., van Hoogstraten, L. M. C., van der Heijden, M. S., Donders, A. R., Franckena, M., Uyl-de Groot, C. A., Leliveld-Kors, A. M., Aben, K. K. H., & Hulshof, M. C. C. M. (2026). Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie. Tijdschrift voor Urologie, 16(2-3), 59–67. https://doi.org/10.1007/s13629-026-00494-8

@article{c8d9e5163d564d578bd2534406e07b4f,

title = "Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie",

abstract = "Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5\% for BPT and 55.3\% for RC (HR 0.84; 95\%-CI 0.69–1.05). Two-year OS was 74.0\% for BPT versus 66.0\% for RC (HR 0.80; 95\%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.",

author = "Katharina Br{\"u}ck and Meijer, \{Richard P.\} and Boormans, \{Joost L.\} and \{de CRAC-studiegroep en de BlaZIB-studiegroep\} and Kiemeney, \{Lambertus A.\} and Witjes, \{J. Alfred\} and \{van Hoogstraten\}, \{Lisa M.C.\} and \{van der Heijden\}, \{Michiel S.\} and Donders, \{A. Rogier\} and Martine Franckena and \{Uyl-de Groot\}, \{Carin A.\} and Leliveld-Kors, \{Annemarie M.\} and Aben, \{Katja K.H.\} and Hulshof, \{Maarten C.C.M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = mar,

day = "2",

doi = "10.1007/s13629-026-00494-8",

language = "Dutch",

volume = "16",

pages = "59–67",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science+Business Media",

number = "2-3",

}

Brück, K, Meijer, RP, Boormans, JL, de CRAC-studiegroep en de BlaZIB-studiegroep, Kiemeney, LA, Witjes, JA, van Hoogstraten, LMC, van der Heijden, MS, Donders, AR, Franckena, M , Uyl-de Groot, CA, Leliveld-Kors, AM, Aben, KKH & Hulshof, MCCM 2026, 'Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie', Tijdschrift voor Urologie, vol. 16, no. 2-3, pp. 59–67. https://doi.org/10.1007/s13629-026-00494-8

TY - JOUR

T1 - Spierinvasieve blaaskanker in Nederland

T2 - oncologische uitkomsten na radicale cystectomie en blaassparende therapie

AU - Brück, Katharina

AU - Meijer, Richard P.

AU - Boormans, Joost L.

AU - de CRAC-studiegroep en de BlaZIB-studiegroep

AU - Kiemeney, Lambertus A.

AU - Witjes, J. Alfred

AU - van Hoogstraten, Lisa M.C.

AU - van der Heijden, Michiel S.

AU - Donders, A. Rogier

AU - Franckena, Martine

AU - Uyl-de Groot, Carin A.

AU - Leliveld-Kors, Annemarie M.

AU - Aben, Katja K.H.

AU - Hulshof, Maarten C.C.M.

PY - 2026/3/2

Y1 - 2026/3/2

N2 - Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

AB - Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

UR - https://www.scopus.com/pages/publications/105031942996

U2 - 10.1007/s13629-026-00494-8

DO - 10.1007/s13629-026-00494-8

M3 - Article

AN - SCOPUS:105031942996

SN - 2211-3037

VL - 16

SP - 59

EP - 67

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 2-3

ER -

Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this